Central Nervous System

Breakthrough treatments for neurological and psychiatric disorders

Neuroscience Innovation

Oracle BioTech develops cutting-edge treatments for Alzheimer's disease, Parkinson's disease, depression, schizophrenia, and other CNS disorders using advanced neuroscience and drug delivery technologies.

Brain Research

Neurodegenerative Diseases

Novel therapeutic approaches targeting protein aggregation and neuroinflammation in Alzheimer's and Parkinson's disease.

  • Anti-amyloid therapies
  • Tau protein modulators
  • Neuroprotective agents
  • Alpha-synuclein inhibitors
Learn More
Psychiatric Treatment

Psychiatric Disorders

Next-generation treatments for depression, anxiety, schizophrenia, and bipolar disorder with improved efficacy and safety profiles.

  • Novel antidepressants
  • Atypical antipsychotics
  • Anxiolytic innovations
  • Mood stabilizer combinations
Learn More

CNS Development Pipeline

Discovery

6 Programs

Novel neurotransmitter targets and blood-brain barrier delivery.

Preclinical

4 Programs

CNS safety and behavioral efficacy studies.

Phase I

2 Programs

First-in-human studies for Alzheimer's and depression treatments.

Phase II

2 Programs

Proof-of-concept in neurodegenerative disease patients.

Phase III

1 Program

Pivotal trial for novel Parkinson's disease therapy.